Whalesbook
📉 Vittek Gahre Janch
Cipla Di Q3 FY'26 Ch Kaghartaa Vich Saal-dar-Saal Rs 7,074 Crore Da Flat Consolidated Revenue Dekhya Geya. Eh Thathrav Mukh Roop Naal Generic Revlimid Di Vigri Vich Umeed Wali Giraawat Karke Hoyi. EBITDA Margin, Hor Aamdani Nu Chhad K, 17.7% Raha, Te Gross Margins 62.8% Rahe, Jehde Dono Lenalidomide Aamdani Vich Kami Te Chaloo Product Mix Karke Prabhavit Huye.
Kul Kharcha 13% YoY Vadh K Rs 3,187 Crore Ho Geya. Eh Vadh Aunde Product Launches Nu Support Karn Lai Research & Development (R&D), Manufacturing Capabilities, Te Talent Acquisition Vich Kite Gye Niyojit Strategic Investments Da Parinaam Si. R&D Kharch 37.4% Vadh K Rs 494 Crore Ho Geya, Jehda Revenue Da 7% Si, Te Isda Dhyaan Product Filings Te Mukh Development Programs Te Si.
Quarter Lai Profit After Tax (PAT) Rs 676 Crore (Sales Da 9.6%) Raha. Is Vich Rs 276 Crore Da Ik Vaar Da Asadharan Kharch Vi Shamil Hai Jehda Nawi Labour Code De Lagu Karn Naal Sambandhit Si.
"Chinta Wala" Mudda:
North America Vich Hoyi Rukavat Ik Mahatvapurna Chinta Si. Is Area Vich Revenue $167 Million Raha. Lenalidomide Nu Chhad K Base Business Vich Double-Digit Growth Dekhnu Mili, Parantu Lanreotide Vich Ik Wada Jhatka Laga. Partner Pharmathen Di Facility Vich US FDA Inspection Karke Nau 483 Observations Mile, Jina Karke Production Nu Temporary Roki Dita Geya. Management Ne Dasya Ki Resupply H1 FY'27 Vich Umeed Hai, Te Cipla Vakhre Manufacturing Sites Nu Evaluate Kar Rahi Hai. Is Rukavat Naal, Umeed Ton Ghat Lanreotide Performance Te Generic Revlimid Billing Cycle De Mukam Hono Ne Management Nu FY'26 EBITDA Margin Guidance Nu Approx 21% Te Sudharen Lai Majboor Kita.
🚀 Ranneetikk Samiksha Te Asar
Cipla Da Desi Business, 'One-India' De Naam Naal Jaani Janda Hai, Ik Mazboot Vadh Da Engine Banea, Jisne 10% YoY Growth Diti. Branded Prescription Business Ne Vi Double-Digit Growth Haasil Kiti, Jisme Respiratory (IPM Vich Pehli Vaar Rs 5,000 Crore Cross Karn Wala), Anti-diabetes, Te Cardiac Varge Mukh Therapy Areas Ne Mazboot Performance Dikhaai. Company Ne Apne 'INR 100 Crore Club' Nu Vadhaya, Jisme Char Nave Brands Judan Naal Total 30 Ho Gye.
Ranneetikk Pehalan Portfolio Nu Mazbooti Dendiye Ne. Ehna Vich Pfizer Naal India Vich Char Brands Lai Marketing Te Distribution Contract Te Bachya Di Pharmaceutical Te Wellness Products Te Dhyaan Den Wali Inzpera Health Sciences Nu Kharedan Da Pukka Contract Shamil Hai. Quarter Vich Nave Product Launch, Jivein Afrezza (India Da Pehla Inhaled Rapid-Acting Insulin) Te Yurpeak (Tirzepatide Therapy), Company De Offerings Nu Hor Mazboot Karde Ne.
🚩 Khatre Te Bhavikh Di Soch
Cipla Lai Mukh Khatre Revlimid Vigri Nu Sambhalna Te US Vich Lanreotide Production Problem Nu Hal Karna Hai. Company Aunde Launches Te Bharosa Kar Rahi Hai, Jisme US Vich Char Mukh Respiratory Products (Jivein Generic Advair) Te FY'27 Lai Plan Kite Gye Teen Peptide Assets Shamil Ne, Jehde Revenue Di Kami Nu Poora Karn Te Lambe Samay Lai Growth Banaye Rakhn Vich Madad Karan Ge.
Investors Lanreotide Resupply Di Timeline Te US Product Launch Pipeline De Lagu Hon Nu Ghaur Naal Dekhan Ge. FY'27 Margins Lai Guidance Annual Operating Plan Final Hon Te Diti Jaavegi. Company Ne 31 December, 2025 Tak Rs 10,229 Crore Di Swasth Net Cash Position Banaye Rakhi, Jehdi Ik Sthir Financial Foundation Farham Kardi Hai.